ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
Lipopeptide Antibiotic Pregnancy: Use only if clearly necessary — limited data

Daptomycin (Prosthetic Joint Infections — Gram-positive)

Brand names: Cubicin

Adult dose

Dose: 6 mg/kg IV once daily (complicated skin and soft tissue); 8–12 mg/kg once daily (bacteraemia/PJI — off-label higher dosing)
Route: Intravenous infusion over 30 minutes
Frequency: Once daily
Max: 12 mg/kg/day (for PJI — higher doses investigational)
LICENSED: Complicated SSTI 4 mg/kg OD, S. aureus bacteraemia 6 mg/kg OD. FOR PJI: 8–10 mg/kg/day is used off-label based on pharmacokinetic/pharmacodynamic data and expert guidelines. Always check CPK before and weekly — myopathy risk. Do NOT use for pneumonia — daptomycin is inactivated by pulmonary surfactant.

Paediatric dose

Dose: 5–10 mg/kg
Route: IV
Frequency: Once daily
Max: 10 mg/kg/day
Paediatric S. aureus infections — under specialist guidance; dosing by age group (neonates use different schedules)

Dose adjustments

Renal

eGFR <30 mL/min: dose every 48 hours (reduce frequency, not dose); CPK monitoring more frequent

Hepatic

No dose adjustment required

Paediatric weight-based calculator

Paediatric S. aureus infections — under specialist guidance; dosing by age group (neonates use different schedules)

Clinical pearls

  • CRITICAL prescribing rule: daptomycin is inactivated by pulmonary surfactant — NEVER use for pneumonia (including haematogenous Staphylococcal pneumonia); must use alternative antibiotic if pulmonary infection is present or suspected
  • Statin interaction: HMG-CoA reductase inhibitors (statins) additively increase myopathy risk with daptomycin — consider withholding statins during daptomycin courses, especially in frail or elderly patients with pre-existing myopathy risk
  • PJI advantage: daptomycin has biofilm-penetrating properties and activity against stationary-phase Staphylococci (which are resistant to many antibiotics) — useful in 2-stage revision arthroplasty for MRSA or glycopeptide-resistant organisms
  • Combination therapy in PJI: daptomycin + rifampicin combination is used for device-retained MRSA PJI — rifampicin penetrates biofilm and prevents daptomycin resistance emergence
  • CPK monitoring: baseline before starting; weekly during treatment; if CPK >5× ULN with symptoms or >10× ULN without symptoms — STOP daptomycin

Contraindications

  • Pulmonary infections (daptomycin inactivated by lung surfactant — will fail)
  • Known hypersensitivity to daptomycin

Side effects

  • Myopathy / rhabdomyolysis — elevated CPK; dose-dependent; reversible on stopping
  • Eosinophilic pneumonia — rare but serious; fever, cough, dyspnoea (paradoxical if used for non-pulmonary infection)
  • Peripheral neuropathy
  • GI effects
  • Elevated LFTs

Interactions

  • Statins — additive myopathy risk; consider statin holiday during daptomycin treatment
  • Other myotoxic drugs — increased CPK elevation risk

Monitoring

  • CPK weekly (myopathy monitoring)
  • Renal function weekly
  • LFTs
  • Signs of eosinophilic pneumonia — dyspnoea, cough, fever
  • Peripheral neurological assessment

Reference: BNFc; BNF 90; IDSA MRSA Guidelines 2011; IDSA Prosthetic Joint Infection Guidelines 2013; SPC Cubicin; BSAC Guidelines. Verify against your local formulary and the latest BNF before prescribing.

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Pathways